

# Tissue Plasminogen Activator

[View the current Tissue Plasminogen Activator InDepth page on BioPortfolio.com \(PDF\)](#)

([http://www.bioportfolio.com/indepth/Tissue\\_Plasminogen\\_Activator.html](http://www.bioportfolio.com/indepth/Tissue_Plasminogen_Activator.html)) - Regularly Updated.

## Recent Publications on Tissue Plasminogen Activator:



- [Postthrombolysis Blood Pressure Elevation Is Associated With Hemorrhagic Transformation.](#)  
*BACKGROUND AND PURPOSE: Reliable predictors of hemorrhagic transformation...*21st November, 2009  
From the Division of Neurology, University of Alberta, Edmonton, Alberta,- Stroke. 2009 Nov 19. ([DOI Direct Link](#))
- [Effects of inhalable particulate matter on blood coagulation.](#)  
*Background: Particulate matter (PM) exposure has been linked to increased...*20th November, 2009  
Department of Clinical and Biological Sciences, University of Insubria,- J Thromb Haemost. 2009 Nov 17. ([DOI Direct Link](#))
- [Inflammatory mechanisms in ischemic stroke: therapeutic approaches.](#)  
*ABSTRACT: Acute ischemic stroke is the third leading cause of death in...*19th November, 2009  
- J Transl Med. 2009 Nov 17;7(1):97. ([DOI Direct Link](#))
- [Intravenous recombinant tissue plasminogen activator for acute stroke in Poland: an analysis based on the Safe Implementation of Thrombolysis in Stroke \(SITS\) Registry.](#)  
*Objectives - Intravenous thrombolysis was conditionally approved in the...*19th November, 2009  
2nd Department of Neurology, Institute of Psychiatry and Neurology,- Acta Neurol Scand. 2009 Nov 16. ([DOI Direct Link](#))
- [Fetal and maternal angiogenic/anti-angiogenic factors in normal and preeclamptic pregnancy.](#)  
*Few studies evaluated angiogenic/anti-angiogenic factors and endothelial...*19th November, 2009  
Instituto Biologia Molecular Celular (IBMC), Universidade Porto, Porto,- Growth Factors. 2009 Dec;27(6):345-351.
- [Platelet Inhibition with Cangrelor in Patients Undergoing PCI.](#)  
*BACKGROUND: Cangrelor, a nonthienopyridine adenosine triphosphate...*17th November, 2009  
From the Duke Clinical Research Institute, Duke University Medical Center,- N Engl J Med. 2009 Nov 17. ([DOI Direct Link](#))
- [Polyelectrolyte multilayer films allow seeded human progenitor derived endothelial cells to remain functional under shear stress in vitro.](#)  
*There is considerable interest in making multilayer films for various...*17th November, 2009  
Inserm, U577, Bordeaux, F-33076 Bordeaux and Universite Victor Segalen- Acta Biomater. 2009 Nov 11. ([DOI Direct Link](#))
- [Influence of antiplatelet pre-treatment on the risk of intracranial haemorrhage in acute ischaemic stroke after intravenous thrombolysis.](#)  
*Background: Pre-treatment with antiplatelet agents (AP) is present amongst...*17th November, 2009

- Stroke Unit, Department of Neurosciences, University Hospital Germans- Eur J Neurol. 2009 Nov 12. ([DOI Direct Link](#))
- [NR2D-containing NMDA receptors mediate tissue plasminogen activator-promoted neuronal excitotoxicity.](#)  
*Although the molecular bases of its actions remain debated, tissue-type...*17th November, 2009  
 [1] INSERM, INSERM U919, Serine Proteases and Pathophysiology of the- Cell Death Differ. 2009 Nov 13. ([DOI Direct Link](#))
  - [Remote Supervision of IV-tPA for Acute Ischemic Stroke by Telemedicine or Telephone Before Transfer to a Regional Stroke Center Is Feasible and Safe.](#)  
*BACKGROUND AND PURPOSE: Because of a shortage of stroke specialists, many...*17th November, 2009  
 From the Massachusetts General Hospital, and the Harvard School of Public- Stroke. 2009 Nov 12. ([DOI Direct Link](#))
  - [Comparison of Partial \(.6 mg/kg\) versus Full-Dose \(.9 mg/kg\) Intravenous Recombinant Tissue Plasminogen Activator Followed by Endovascular Treatment for Acute Ischemic Stroke: A Meta-Analysis.](#)  
*ABSTRACT BACKGROUND In the treatment of acute ischemic stroke, intravenous...*17th November, 2009  
 From the Zeenat Qureshi Stroke Research Center, Department of Neurology,- J Neuroimaging. 2009 Nov 10. ([DOI Direct Link](#))
  - [Antiplatelet Therapy in Combination with rt-PA Thrombolysis in Ischemic Stroke \(ARTIS\): Rationale and Design of a Randomized Controlled Trial.](#)  
*Background: Thrombolysis with recombinant tissue plasminogen activator...*13th November, 2009  
 Department of Neurology, Academic Medical Centre, University of Amsterdam,- Cerebrovasc Dis. 2009 Nov 10;29(1):79-81. ([DOI Direct Link](#))
  - [Enhancement of fibrinolysis by gel-filtered platelets and its quenching by cytochalasin B and GPIIb/IIIa antagonists.](#)  
*The effects of gel-filtered platelets on euglobulin clot lysis time (ECLT)...*12th November, 2009  
 Department of Physiology, Hamatsu University School of Medicine, 1-20-1,- Pharmacol Rep. 2009 Sep-Oct;61(5):877-84.
  - [Letter by Brown and Pretorius regarding article, "effect of sulfaphenazole on tissue plasminogen activator release in normotensive subjects and hypertensive patients".](#)  
*The effects of gel-filtered platelets on euglobulin clot lysis time (ECLT)...*11th November, 2009  
 - Circulation. 2009 Nov 10;120(19):e159; author reply e160. ([DOI Direct Link](#))
  - [Inhibitory effect on LPS-induced retinal microglial activation of downregulation of t-PA expression by siRNA interference.](#)  
*PURPOSE: This study investigated the expression and release of tissue...*11th November, 2009  
 Department of Ophthalmology, Eye, Ear, Nose and Throat Hospital of Fudan- Curr Eye Res. 2009 Jun;34(6):476-84.

## BioNews Results for Tissue Plasminogen Activator

- [Tissue Plasminogen Activator still mostly used to treat acute stroke cases](#)  
*PharmaBiz: Oct 31 2009 3:40AM Matching: tissue plasminogen activator*
- [BleedScore Helps Predict Superficial Bleeding During Antiplatelet Therapy](#)  
*TCTMD.com: Oct 30 2009 12:56PM Matching: tissue plasminogen activator*





## Tissue Plasminogen Activator Patents:

- 7601718- [Compositions useful as inhibitors of protein kinases](#)
- 7608260- [Stabilized immunoglobulins](#)
- 7608277- [Tuberculosis nucleic acids, polypeptides and immunogenic compositions](#)
- 7608406- [Diagnostic markers of stroke and cerebral injury and methods of use thereof](#)
- 7608415- [Analysis of intracellular modifications](#)
- 7608423- [Expanding the eukaryotic genetic code](#)
- 7608426- [Polynucleotides encoding mammalian cytokine-like factor 7](#)
- 7608431- [Fed-batch process for production of erythropoietin in human embryonic retina cells that express adenovirus E1A](#)
- 7608579- [Lung volume reduction using glue compositions](#)
- 7608586- [Soluble low-density lipoprotein receptor related protein binds directly to Alzheimer's amyloid-beta peptide](#)
- 7608640- [Glycine betaine and its use](#)
- 7605236- [Antibodies that immunospecifically bind to B lymphocyte stimulator protein](#)
- 7605231- [Gelatin derivatives and high-molecular micelle comprising the derivatives](#)
- 7605182- [Compounds that selectively bind to membranes of apoptotic cells](#)
- 7601731- [Antimicrobial flush solutions](#)
- 7601838- [2-Alkyl/aryl sulphonyl-1,2,3,4-tetrahydro-9H-pyrido \(3,4-b\) indole-3-carboxylic acid esters/amides useful as antithrombotic agents](#)
- 7604799- [EphA4 Antibodies](#)
- 7604818- [Polymers of fluorinated monomers and hydrocarbon monomers](#)
- 7604952- [Detection and determination of the stages of coronary artery disease](#)
- 7604960- [Transient protein expression methods](#)
- 7604989- [Inhibition of apoptosis process and improvement of cell performance](#)
- 7605127- [Truncated hepatocyte growth factor variant protein HGF/NK2](#)
- 7605142- [Expression of cyclin G1 in tumors](#)
- 7605172- [Thiazolo-naphthyl acids](#)
- 7608681- [Methods and compositions for prolonging elimination half-times of bioactive compounds](#)
- 7608694- [Antibody molecules having specificity for human IL-1.beta.](#)
- 7615618- [Oligonucleotides comprising a non-phosphate backbone linkage](#)
- 7616991- [Method for digital cardiac rhythm management](#)
- 7618434- [Devices and methods for disruption and removal of luminal occlusions](#)
- 7618639- [Synergistic phytochemical compositions](#)
- 7618775- [Expanding the eukaryotic genetic code](#)
- 7618799- [Bacterial leader sequences for increased expression](#)
- 7618936- [Methods for treating and diagnosing cancer with WNT inhibitory Factor-1 \(WIF-1\)](#)
- 7618948- [Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA](#)
- 7618949- [Drug-eluting stents coated with P2Y.sub.12 receptor antagonist compound](#)
- 7619062- [PRO214 polypeptides](#)
- 7615568- [Antithrombotic ethers](#)
- 7615219- [Inhibition of PACAP signalling for the prevention and treatment of thrombocytopenia](#)
- 7612250- [Nuclear transfer embryo formation method](#)
- 7611532- [Coated implantable medical device](#)

- 7611533- [Coated implantable medical device](#)
- 7611708- [Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies](#)
- 7611879- [27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 molecules and uses therefor](#)
- 7611884- [Toxoplasma gondii nucleic acid molecules](#)
- 7612041- [Isolated activin-binding ActRIIa polypeptide comprising the SEQ ID NO: 7 and uses for promoting bone growth](#)
- 7612047- [Degradation-resistant mononucleoside phosphate compounds](#)
- 7612075- [Substituted oxoazaheterocyclyl compounds](#)
- 7612091- [Caspase inhibitors and uses thereof](#)
- 7612178- [Anti-IGF-1R antibodies and uses thereof](#)
- 7620502- [Methods for identifying sets of oligonucleotides for use in an in vitro recombination procedure](#)

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

